Results 31 to 40 of about 63,987 (250)

Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

open access: yesCardio-Oncology, 2020
Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li   +7 more
doaj   +1 more source

Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice

open access: yesPharmaceuticals, 2023
Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci   +4 more
doaj   +1 more source

Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT [PDF]

open access: yes, 2017
Background: Preclinical studies have reported that a single treadmill session performed 24 h prior to doxorubicin provides cardio-protection. We aimed to characterize the acute change in cardiac function following an initial doxorubicin treatment in ...
Shave, R. E.   +31 more
core   +1 more source

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]

open access: yesPLoS ONE, 2015
Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard   +7 more
doaj   +1 more source

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials [PDF]

open access: yes, 2010
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.Methods: Randomized controlled ...
Gill Levitt   +29 more
core   +2 more sources

Doxorubicin Selectively Inhibits Brain versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes [PDF]

open access: yes, 1999
Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes.
Gardner, D. G.   +2 more
core   +1 more source

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

open access: yesBMC Cancer, 2008
Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei   +9 more
doaj   +1 more source

Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients

open access: yesBMC Veterinary Research, 2021
Background Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a “one size fits all” approach to more personalized, patient-oriented treatment strategies.
Kristine Walters   +9 more
doaj   +1 more source

PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells [PDF]

open access: yes, 2012
We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis ...
Dittmann, Kai   +37 more
core   +1 more source

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

open access: yesTumor Biology, 2017
The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin.
Yun Sun Lee   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy